{
    "Clinical Trial ID": "NCT00438100",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Capecitabine Arm",
        "  Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.",
        "  Capecitabine: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.",
        "INTERVENTION 2: ",
        "  S-1 Arm",
        "  S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.",
        "  S-1: 80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Biopsy-diagnosed breast cancer with metastasis in multiple organs",
        "  Performance Status (World Health Organization :WHO) 0-2",
        "  Functions below are maintained in major organs:",
        "  Leukocyte count: 4,000/mm3 to 12,000/mm3",
        "  Neutrophil count: >2,000/mm3 or more",
        "  Platelet count: <100,000/mm3 or more",
        "  Hemoglobin: >9.5 g/dL",
        "  Total bilirubin: >1.5 mg/dL",
        "  AST(GOT): within twice a normal upper value in an institution",
        "  AST(GPT): within twice a normal upper value in an institution",
        "  BUN: < 25 mg/dL",
        "  Creatinine: within a normal upper value in the institution",
        "  24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula)",
        "  Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85",
        "  Written informed consent will be obtained for patients for entering this study",
        "Exclusion Criteria:",
        "  Patients with synchronous multiple cancers",
        "  Complicated with infection",
        "  Fever from suspected infection",
        "  Metastasis to the central nerve system",
        "  A history of ischemic cardiac diseases",
        "  Active gastrointestinal ulcer",
        "  Severe nerve disorder",
        "  Women who are potentially pregnant, pregnant, or breast-feeding",
        "  Severe drug allergy",
        "  Severe suppression of the bone marrow",
        "  Severe renal disorder",
        "  Being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy)",
        "  Being treated with flucytosine",
        "  Complicated with the infection onset which a study doctor assesses to be inappropriate for this study"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival",
        "  [Not Specified]",
        "  Time frame: The follow up period will be two years after the last dose has been administered.",
        "Results 1: ",
        "  Arm/Group Title: Capecitabine Arm",
        "  Arm/Group Description: Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.",
        "  Capecitabine: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.",
        "  Overall Number of Participants Analyzed: 71",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: years  1.2        (0.76 to 2.04)",
        "Results 2: ",
        "  Arm/Group Title: S-1 Arm",
        "  Arm/Group Description: S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.",
        "  S-1: 80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.",
        "  Overall Number of Participants Analyzed: 65",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: years  1.3        (0.96 to 2.68)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/71 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/65 (0.00%)"
    ]
}